This study is recruiting. It focuses on depression and currently lists participation information in Canada.
This study is comparing Psilocybin 25 mg with placebo for people with Treatment-resistant Depression. Participants receive Psilocybin 25 mg or placebo and complete study visits and assessments. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
The official record suggests in-person participation through a lab, with sites including Centre for Addiction and Mental Health in Toronto. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include pregnancy or breastfeeding and active substance or alcohol problems that could affect the results. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Canada.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
This study is sponsored by Centre for Addiction and Mental Health, a hospital or academic medical center. The Centre for Addiction and Mental Health is a mental health hospital and research center. The sponsor is based in Canada. Sponsor website: https://www.camh.ca. You can verify the sponsor and study responsibility in the official registry record.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.